Impact of age on tumor size in vulvar cancer: A multicenter study by the Francogyn group.

Age Tumor size Vulvar cancer

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
13 Jun 2024
Historique:
received: 17 03 2024
revised: 31 05 2024
accepted: 11 06 2024
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 20 6 2024
Statut: aheadofprint

Résumé

Vulvar cancer is a rare pathology affecting mainly elderly women. This study aims to evaluate the impact of age on tumor size in vulvar cancer. This was a multicenter retrospective observational study carried out between January 1, 1998, and December 31, 2020, in patients operated on for vulvar cancer. Univariate analysis was performed according to patients' age ≥ or <65 years. Factors associated with tumor size found to be significant according to age were then included in a multiple linear regression model. Of the 382 patients included, there were 133 patients aged <65 years and 249 ≥ 65 years. Radical total vulvectomy surgeries were more frequently performed in women ≥65 years (n = 72 (28.9 %) versus n = 20 (15 %); p = 0.004). The median histological tumor size and interquartile range was 20 mm [13-29] in the <65 years and 30 mm [15-42] in patients ≥65 years (p = 0.001). Multiple linear regression showed that age ≥65 years had a regression coefficient of 7.15 95 % CI [2.32; 11.99] (p = 0.004), constituting a risk factor for larger histological tumour size. Patients aged ≥65 years old had a higher early complication rate (n = 150 (62 %) versus n = 56 (42.7 %), p = 0.001). They also had a greater risk of recurrence (HR = 1.89 (95%CI (1.24-2.89)), p = 0.003) with a worse overall survival (HR = 5.64 (95%CI (1.70-18.68)), p = 0.005). Age is a risk factor for larger tumor size, leading to more radical surgery and a greater risk of complications in already fragile patients, with a greater risk of recurrence and an impact on overall survival.

Identifiants

pubmed: 38901290
pii: S0748-7983(24)00534-1
doi: 10.1016/j.ejso.2024.108482
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108482

Informations de copyright

Copyright © 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

E Raimond (E)

Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, Reims Champagne Ardennes University, Reims, France; EA 7285 Laboratory Risk Management in Women's and Perinatal Health, University of Paris Sud-Saclay, France. Electronic address: eraimond@chu-reims.fr.

Y Kerbage (Y)

Lille University Hospital Center, Gynecological and Breast Cancer Surgery, 2 Avenue Oscar Lambret, 59037, Lille, France; University of Lille, Inserm Unit U1189, OncoThai: Laser-Assisted Therapies and Immunotherapies for Oncology, 59000, Lille, France.

L Ouldamer (L)

Department of Obstetrics and Gynaecology, Regional University Hospital Center of Tours, Bretonneau Hospital, Tours, France; INSERM U1069, Université François-Rabelais, Tours, France.

S Bendifallah (S)

Department of Obstetrics and Gynaecology, Tenon Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

X Carcopino (X)

Department of Obstetrics and Gynaecology, Hôpital Nord (APHM), Aix-Marseille University (AMU), Univ Avignon, CNRS, IRD, IMBE UMR 7263, 13397, Marseille, France.

M Koskas (M)

Department of Obstetrics and Gynaecology, Bichat - Claude Bernard Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France; ECEVE U1123, National Institute of Health and Medical Research, Paris Cité University, Paris, France.

P A Bolze (PA)

Department of Gynecological Surgery and Oncology, Obstetrics, Pierre Bénite, Université Lyon 1, CICLY EA3738, Hospices Civils de Lyon, University Hospital Lyon Sud, Lyon, France.

V Lavoué (V)

Department of Obstetrics and Gynaecology, University Hospital Center of Rennes, South Hospital, Rennes, France.

T Gauthier (T)

Department of Obstetrics and Gynaecology, Mère - Enfant Hospital, University Hospital Center of Limoges, Limoges, France.

O Graesslin (O)

Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, Reims Champagne Ardennes University, Reims, France.

A Fauconnier (A)

EA 7285 Laboratory Risk Management in Women's and Perinatal Health, University of Paris Sud-Saclay, France; Department of Obstetrics and Gynaecology, Intercommunal Hospital Center of Poissy, Poissy, France.

C Huchon (C)

ECEVE U1123, National Institute of Health and Medical Research, Paris Cité University, Paris, France; Department of Obstetrics and Gynaecology, Lariboisiere University Hospital, University Paris Cité, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.

Classifications MeSH